101. Reversal of Elevated International Normalized Ratios and Bleeding with Low-Dose Recombinant Activated Factor VII in Patients Receiving Warfarin
- Author
-
R. Steven Tharratt, Dean Williamson, Richard H. White, Ron C Regalia, Robert C. Gosselin, Jeffrey H. King, William E. Dager, and Timothy E Albertson
- Subjects
Male ,Adolescent ,Critical Care ,medicine.drug_class ,Hemorrhage ,Factor VIIa ,law.invention ,law ,Blood plasma ,medicine ,Humans ,Pharmacology (medical) ,International Normalized Ratio ,Prospective Studies ,Prospective cohort study ,Blood Coagulation ,Aged ,Aged, 80 and over ,Clinical pharmacology ,Coagulants ,Vascular disease ,business.industry ,Anticoagulant ,Warfarin ,Anticoagulants ,Factor VII ,Middle Aged ,medicine.disease ,Intensive care unit ,Recombinant Proteins ,Anesthesia ,Female ,Fresh frozen plasma ,business ,medicine.drug - Abstract
Study Objective. To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events. Design. Prospective observational study. Setting. Intensive care unit of a 500-bed university-affiliated hospital. Patients. Sixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event. Intervention. Patients received rFVIIa 1.2 mg for reversal of anticoagulation. Measurements and Main Results. Patients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross-checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean ± SD dose of rFVIIa 16.3 ± 4.1 μg/kg (range 11–25 μg/kg) reduced the mean INR from 2.8 ± 1.6 (range 1.44–6.34) to 1.07 ± 0.27 (range 0.86–1.92, p
- Published
- 2006
- Full Text
- View/download PDF